Lymphocyte counts and infection rates
Open Access
- 1 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To evaluate lymphocyte counts and incidences of infections in patients with primary progressive MS (PPMS) receiving fingolimod 0.5 mg/d or placebo over 5 years during the INFORMS study, to assess infection rates with longer-term treatment. Methods INFORMS was a randomized, multicenter, double-blind, placebo-controlled, parallel-group, phase 3 study of the sphingosine 1-phosphate receptor modulator fingolimod in patients with PPMS. Lymphocyte counts and incidences of infections were compared in patients receiving fingolimod or placebo. Infection rates were assessed in patients receiving fingolimod according to nadir and mean absolute lymphocyte count (ALC). Results Overall, 336 patients received fingolimod 0.5 mg/d (total exposure: 908.1 patient-years), and 487 received placebo (1,423.5 patient-years). In patients receiving fingolimod, mean ALC decreased by approximately 70% in the 2 weeks following treatment initiation and remained stable throughout the study. The incidences of all infections in the fingolimod and placebo groups were similar (53.6 vs 51.9 per 100 patient-years). The most common infections in patients receiving fingolimod were urinary tract infections (5.7 per 100 patient-years), upper respiratory tract infections (4.2 per 100 patient-years), and influenza (3.2 per 100 patient-years); incidences were similar in the placebo group (5.9, 4.2, and 3.1 per 100 patient-years, respectively). There was no apparent association between nadir or mean ALC and incidence of infection-related adverse events. Conclusions In patients with PPMS, long-term treatment with fingolimod 0.5 mg/d for up to 5 years led to an expected decrease of approximately 70% in mean ALC and did not appear to correlate with increased risk of infection. Classification of evidence Because this is a secondary analysis, this study provides Class II evidence that long-term PPMS treatment with fingolimod decreased mean ALC by approximately 70%, but did not significantly increase infection risk.Keywords
This publication has 22 references indexed in Scilit:
- Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated PatientsFrontiers in Immunology, 2018
- Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trialTherapeutic Advances in Neurological Disorders, 2018
- Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic SettingInternational Journal of MS Care, 2017
- Aging and multiple sclerosisMultiple Sclerosis Journal, 2016
- Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidenceTherapeutic Advances in Neurological Disorders, 2016
- Sphingosine 1-Phosphate Receptor Modulators in Multiple SclerosisCNS Drugs, 2015
- Varicella-Zoster Virus Infections in Patients Treated With FingolimodJAMA Neurology, 2015
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosisNeurology, 2011
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005